Caledonia Investments acquires minority stake in BioAgilytix

Caledonia Investments acquires minority stake in BioAgilytix

Caledonia Investments acquires minority stake in BioAgilytix – Caledonia has invested a minority stake in US-based pharmaceutical services business BioAgilytix, which specialises in bioanalytical testing solutions for molecule research and development. Caledonia has invested alongside Cobepa (a Belgium and US-based investment company), which it has a 5% shareholding in. BioAgilytix has offices in Raleigh, North Carolina and Hamburg, Germany – they employ over 250 staffmembers.

Jim Datin, President and CEO of BioAgilytix, has said previously that, “We have built a team with an excellent reputation for quality science and superior service, which has allowed us to expand our work with existing customers and grow our customer base significantly over the past several years…Going forward, Cobepa will provide additional capital as well as access to their broad international network, which will empower us to continue serving our clients’ evolving and expanding bioanalytical needs. It will enable us to invest in further building out our talented team, expanding our advanced lab facilities in both the USA and Europe, and adding adjacent bioanalytical services that will benefit our customers.”

Peter Connolly, the managing director at Cobepa North America, commented, “We are pleased to partner with BioAgilytix in the next phase of its development, providing the resources necessary to extend its impressive track record, retain and add to its respected team, and solidify its position as the premier worldwide provider of large molecule bioanalytical testing services.”

About BioAgilytix

BioAgilytix is a leading bioanalytical testing laboratory specializing in large molecule bioanalysis. With laboratory locations in North Carolina’s research triangle area and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development and release testing of biologics across a number of industries and disease states. BioAgilytix offers assay development, validation, and sample analysis under non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e. product release testing, stability testing, etc.).

CLDN : Caledonia Investments acquires minority stake in BioAgilytix

Leave a Reply

Your email address will not be published. Required fields are marked *